


### Remarks

Claims 9, 25 and 26 are pending. Claims 1-8 and 10-24 have been cancelled. Claims 25 and 26 have been added. There being no issues of new matter entry of the following amendment is hereby requested.

In response to the restriction requirement Applicants hereby elect without traverse to prosecute in this application the subject matter of Group II (claims 9-15) drawn to a siRNA composition of a siRNA sequence. Furthermore, Applicant selects SEQ ID No. 3 as the siRNA composition. Applicants reserve the right to prosecute in one or more divisional applications whatever subject matter is not allowed here. Claim 25 directed to substantially purified compositions of SEQ ID. No. 3 and Claim 26 directed to a composition consisting of SEQ ID. No. 3 have been added.

It not believed that any other fees are required beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a) and any fees required therefore are hereby authorized to be charged to our Deposit Account No. 02-2955.

Respectfully submitted,



David A. Dow  
Attorney for Applicant(s)  
Reg. No. 46,124

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Tel.: (203) 791-6214  
May 1, 2006